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Abstract 
 
There has been a significant increase in the number of diagnostic and prognostic models published 
in the last decade.  Testing such models in an independent, external validation cohort gives some 
assurance the model will transfer to a naturalistic, healthcare setting.  Of 2,147 published models in 
the PubMed database, we found just 120 included some kind of separate external validation cohort.  
Of these studies not all were sufficiently well documented to allow a judgement about whether that 
model was likely to transfer to other centres, with other patients, treated by other clinicians, using 
data scored or analysed by other laboratories.  We offer a solution to better characterizing the 
validation cohort and identify the key steps on the translational pathway for diagnostic and 
prognostic models. 
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Background 
 
The last decade has seen a marked increase in diagnostic and prognostic prediction models in 
medicine.   The growth of interest in biomarkers, personalized and stratified medicine, coupled with 
the rise of machine learning and statistical algorithms aiding the building of such diagnostic and 
prognostic tools1-3 has led to a proliferation of prediction models in recent years - see 
Supplementary Figure 1.  However, the quality and reporting of studies to support such prediction 
models is often poor4 prompting the development of reporting guidelines for studies of 
observational data5, tumour markers6, diagnostic accuracy7, genetic risk prediction3, and 
multivariable prediction models4– the STROBE, REMARK, STARD, GRIPS and TRIPOD guidelines 
respectively.  In particular, the TRIPOD guideline offers specific recommendations around studies 
developing or validating prediction models4.   
As a result, most studies now use some kind of validation cohort to evaluate the model.  Usually 
some portion of the data is retained for testing models.  Internal validation tools – such as split-
sampling, cross validation, and bootstrapping - are an essential part of the model building process.  
Internal validation directly addresses sampling variability: minimizing the risk of over-fitting models; 
minimizing the impact of outliers or other influential data; and guarding against chance partitions of 
the data impacting upon the model.  Unfortunately, they tell us little or nothing about variation in 
the study population or clinical setting.  They tend to be overoptimistic giving good “apparent” 
performance while giving little or no assurance on how the prediction model is likely to perform in 
real life8.  Internal validation is a necessary, but not sufficient, condition to ensure the robust 
transfer of diagnostic and prognostic tools.  However, in medicine it is critically important to know if 
the model generalizes to other patients, assessed and treated by other clinicians, at other sites, 
using assays performed in other laboratories.    
 
Main Text 
 
This problem is essentially one of technology transfer or ‘transportability’9.  And internal validation 
methods tell us little or nothing about how the technology – the prediction model – performs when 
transferred to another setting.  For this reason, the performance of a model must be tested using 
data other than that used for the model development10,11 12.  An independent, external validation 
cohort provides much stronger evidence that a prognostic or diagnostic model will perform in real 
life13.  Without such a cohort, the “ecological validity” of the model may be severely limited.  Bleeker 
et al 8 for example give an early paediatric infection example demonstrating how disappointing such 
prediction models can be when transferred to populations other than those in which they were 
initially developed.  More recently, Sahami et al report on the limitations of prognostic models for 
proctocolectomy14, and Damen et al 15 report on the limitations of cardiovascular risk models. 
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While external validation studies may be critical to understanding the performance of such models 
in real life, unfortunately such studies are relatively rare16-18.  We searched the PubMed database for 
diagnostic and prognostic models published in medicine through to September 2016 (see 
Supplementary Table 1).  The majority of studies employed some, often limited, form of internal 
validation.  Of 2,147 published papers on prognostic or diagnostic modelling, 323 claimed to have 
tested, verified or validated the model using an independent OR external validation cohort – see 
Table 1.  And of these studies, just 120 claimed to have tested, verified or validated the model using 
a separate independent AND external validation cohort.   However, upon further review, not all of 
these 120 studies can be considered truly independent validation studies.  Some confuse internal 
and external validation; others employ relatively ‘soft’ validation methods.  For example, time-
separated cohorts from the same centre, using the same protocols, examined and treated by the 
same clinicians, using test results from the same laboratory, may not capture all the sources of 
variability in a truly independent cohort.  Even when models are validated using groups of patients 
from other centres, the laboratory analysis, diagnosis or scoring of results may be performed by the 
same team from a single centre – see Figure 1. 
 
Table 1:  Validation of diagnostic and prognostic models in medicine for the period 1970-2016.  Of 
2,147 published models, just 120 included an external validation cohort.  
 
Source: PubMed 
 
As part of the validation process it is essential to be clear what sources of variability - patient, 
clinician, clinical setting – are captured by the validation cohort.  We need to know whether the 
validation cohort gives us any reassurance that a decision tool will transfer to other centres, other 
patients, other clinicians, in other clinical settings.  Without such assurance it is most unlikely that 
model performance will be reproducible.  To this end, we offer the Newcastle ‘Validation Cohort’ 
Checklist to assist reviewers in reality checking the validation and identifying those sources of 
variability captured by the validation cohort (Table 2).  The goal is to provide greater assurance that 
a model will perform in a real world healthcare setting. 
  
Additional Search Terms  prognostic model diagnostic model prognostic AND diagnostic
1,584                            563                               2,147                                                         
AND validation OR test OR verification 538                                208                               746                                                             
AND independent OR external 288                                35                                  323                                                             
AND external validation 110                                10                                  120                                                             
Building Reality Checks into the Translational Pathway for 
Diagnostic and Prognostic Models 
 
Lendrem et al Page 5 
 
 
Table 2: The Newcastle ‘Validation Cohort’ Checklist: the checklist captures some of the key sources 
of variability in a validation cohort for reality checking of diagnostic and prognostic models.   
Key Questions  Reality Checks 
The validation cohort offers some assurance that the model works: 
 At different sites?  Geographical  
At different times?  Temporal  
Scored or diagnosed by different clinicians?  Clinical   
Analyzed in different laboratories?  Laboratory  
For different patient populations?  Population  
  
 
While diagnostic and prognostic models may be of some value even without such external 
validation, it is not unreasonable for funding agencies to expect clarity around the generalizability of 
those models, proposed validation plans and the prospective translational pathway.  We urge 
researchers to be explicit about the sources of variability captured by the external validation cohort.  
The validation cohort needs to be sufficiently well documented that we can tell whether the model 
is likely to transfer to other centres, with other patients, treated by other clinicians, using data 
scored or analysed by other laboratories. 
Of course, model validation and impact studies are but one step on the translational pathway.  For 
our models to translate to real patient benefit, we need to build qualification and monitoring 
processes into that pathway – see Figure 2.  Ultimately, to apply a model we need to know whether 
that model is valid in a given healthcare setting, healthcare trust or even an individual practice.  Even 
an externally validated prognostic or diagnostic model is no more than a plausible candidate for 
routine use in the clinic.  Without some kind of qualification study, it does not establish that the 
model is valid in an individual healthcare setting.   Even after the validation and qualification of a 
prospective model, we need ‘production’ systems in place to monitor the performance of that 
model in a naturalistic healthcare setting.  This permits models to be reviewed and recalibrated to 
reflect changes in the patient population, clinical protocols and training.  The analogy we draw is 
that of the clinical trial process.  The movement from development, through recalibration and 
validation, to qualification and monitoring parallels that of drug development: from early proof-of-
concept studies, through dose finding to Phase 3 clinical trials, followed by post-marketing studies 
and surveillance.  The emergence of national registries and access to ‘big data’ health records open 
up exciting possibilities for the external validation, recalibration and ‘real-time, real-world’ updating 
of diagnostic and prognostic tools19.  Currently, it is questionable whether we have the national 
systems and data access permitting routine monitoring of such models.   But that must be our goal. 
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Conclusions 
 
While the internal validation cohort is an important part of the model building process, the external 
validation cohort gives greater assurance that a diagnostic or prognostic model will translate to the 
clinic.  However, researchers need to be explicit about the sources of variability captured by the 
external validation cohort.  The validation cohort needs to be sufficiently well documented that we 
can tell whether the model is likely to transfer to other centres, with other patients, treated by other 
clinicians, using data scored or analysed by other laboratories. 
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Figures 
 
 
 
 
 
 
  
Figure 1: In order to assess the transferability of a diagnostic or prognostic model we need to be 
explicit about the sources of variability captured by our validation cohort.  Imagine a model 
developed at Centre 1 that was trained and tested on a population of patients T.  This model 
might be expected to perform well on patients in the validation cohort V1 .  However, these 
patients are derived from the same demographic region and treated using a shared clinical 
protocol.  Evaluating performance at a separate centre – Centre 2 – gives greater assurance that 
the model will travel to other centres in other regions.  However, if this validation cohort includes 
some patients treated by the same physician, with test results performed at a shared laboratory, 
using images scored by the same radiographer then the performance of the model is 
unrealistically optimistic – the apparent performance is high.  Excluding these individuals, E, 
from the validation cohort V2 gives a separate, independent external validation cohort.   This 
gives a more robust assessment of model performance.    
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Figure 2: For diagnostic and prognostic models to translate to real patient benefit we need a 
translational pathway characterised by 1) good internal validation during the modelling process, 
2) well designed impact studies with well defined external validation cohorts during the 
validation process, 3) qualification studies to evaluate the tool in an individual setting, and 4) 
systems to monitor and feedback on model performance in real world healthcare settings. 
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Supplementary Data 
 
Supplementary Figure: 
  
Supplementary Figure 1: Diagnostic and prognostic models published in medical journals 
between 1980-2015.  The last ten years have seen a marked rise in published models reflecting 
the growing interest in biomarkers, stratified and personalized medicine, together with the 
development of machine learning algorithms and other statistical  tools aiding the building of 
such models. 
 
[Source: PubMed] 
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Supplementary Table: 
 
Supplementary Table 1:  NCBI search terms and filters for diagnostic and prognostic models 
published in PubMed database medical journals through to 01/09/2016.   
 
Source: NCBI  
   
Note:   In this paper we focus on prediction models.  While alternative search terms - such as “prognostic tool” 
or “diagnostic tool” - increase the number of papers, refining the search using terms such as “internal 
validation” or “external validation” or “validation cohort” or “independent validation” generates a similar 
pattern of results.  For example a search through to 01 Sept 2016 for “prognostic tool” in the [Title/Abstract] 
returned 1,715 hits.  Refining the search to papers with the terms “validation” or “confirmation” or “testing” 
or “checking” reduces the search to just 232 hits.  A specific search for the term “validation” returned just 116 
hits: even extending the search to [All Fields] returned just 136 papers.  Narrowing the search to papers 
including “external validation” returned just 19 papers even after extending the search to [All Fields].   
  
Models PubMed Search Terms Results
prognostic Search "prognostic model"[Title/Abstract] Filters: Publication date to 2016/09/01 1,584                  
Search ((((prognostic model[Title/Abstract] AND ( "0001/01/01"[PDat] : "2016/09/01"[PDat] ))) AND 
((validation[Title/Abstract]) OR (verification[Title/Abstract]) OR (test[Title/Abstract])) Filters: Publication 
date to 2016/09/01
538                     
Search (((((((((prognostic model[Title/Abstract] AND ( "0001/01/01"[PDat] : "2016/09/01"[PDat] ))) AND 
((validation[Title/Abstract]) OR (verification[Title/Abstract]) OR (test[Title/Abstract]))) AND ( 
"0001/01/01"[PDat] : "2016/09/01"[PDat] ))) AND (independent[Title/Abstract] OR external[Title/Abstract] 
) ( AND ( "0001/01/01"[PDat] : "2016/09/01"[PDat] )) Filters: Publication date to 2016/09/01
288                     
Search (((((((prognostic model[Title/Abstract] AND ( "0001/01/01"[PDat] : "2016/09/01"[PDat] ))) AND 
((validation[Title/Abstract]) OR (verification[Title/Abstract]) OR (test[Title/Abstract]))) AND ( 
"0001/01/01"[PDat] : "2016/09/01"[PDat] ))) AND external validation[Title/Abstract] Filters: Publication 
date to 2016/09/01
110                     
diagnostic Search "diagnostic model"[Title/Abstract] Filters: Publication date to 2016/09/01 563                     
Search ((((diagnostic model[Title/Abstract] AND ( "0001/01/01"[PDat] : "2016/09/01"[PDat] ))) AND 
((validation[Title/Abstract]) OR (verification[Title/Abstract]) OR (test[Title/Abstract])) Filters: Publication 
date to 2016/09/01
208                     
Search (((((((((diagnostic model[Title/Abstract] AND ( "0001/01/01"[PDat] : "2016/09/01"[PDat] ))) AND 
((validation[Title/Abstract]) OR (verification[Title/Abstract]) OR (test[Title/Abstract]))) AND ( 
"0001/01/01"[PDat] : "2016/09/01"[PDat] ))) AND (independent[Title/Abstract] OR external[Title/Abstract] 
) ( AND ( "0001/01/01"[PDat] : "2016/09/01"[PDat] )) Filters: Publication date to 2016/09/01
35                       
Search (((((((diagnostic model[Title/Abstract] AND ( "0001/01/01"[PDat] : "2016/09/01"[PDat] ))) AND 
((validation[Title/Abstract]) OR (verification[Title/Abstract]) OR (test[Title/Abstract]))) AND ( 
"0001/01/01"[PDat] : "2016/09/01"[PDat] ))) AND external validation[Title/Abstract] Filters: Publication 
date to 2016/09/01
10                       
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